Navigation Links
Diabetes Research Institute Foundation’s (DRIF) CEO Joins Healthcare Holdings Group, Inc. Board of Directors
Date:12/3/2012

Boca Raton, FL (PRWEB) December 03, 2012

Healthcare Holdings Group, Inc. (HCH) is pleased to announce the addition of Mr. Robert A. Pearlman, current CEO of the Diabetes Research Institute Foundation (DRIF), to its Board of Directors.

Mr. Pearlman has long been aware of the company’s Personal Health Records (PHR) product--AccessMyRecords.com—and with their recent growth into the Electronic Health Records (EHR) market, Mr. Pearlman welcomed the opportunity to become an active Board member.

HCH’s Chairman and CEO, Mr. Lenny Tambasco, said “We are honored to have the insight and experience Mr. Pearlman brings to our entire team and corporate culture.” “I’m excited about their technological achievements and believe in the company’s commitment.” said Mr. Pearlman. “Their EHR suite of products can ultimately benefit many people who suffer chronic conditions, provide support to their families, and the physicians that treat them.” He went on to say “the Diabetes Research Institute Foundation’s cornerstone belief is that tomorrow is not soon enough to cure those living with diabetes….this company and their products answer the call to bring tomorrow’s medical technology into the hands of the people today.”

About Mr. Robert A. Pearlman
Mr. Pearlman became a Board Member of Healthcare Holdings Group, Inc. in 2012 and continues to serve as CEO of the Diabetes Research Institute Foundation. He joined DRIF in 1993 as Executive Vice President, and served in this role until 2003, when he was elected to his current position by the national board of directors. During his tenure, the organization has enjoyed exponential growth and revenues have increased more than twenty-fold. Working within the fundraising arena for more than 35 years, Mr. Pearlman is well-known and highly respected in business and philanthropic communities worldwide. He has served in high-level positions for various organizations in the U.S. and abr
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes
3. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
4. A molecule central to diabetes is uncovered
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Novo Nordisk To Award $80,000 To Local Programs That Help People Living With Diabetes In Detroit As Part Of Educational Initiative
7. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
8. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
9. Low testosterone levels could raise diabetes risk for men
10. New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients
11. Gut Microbiota Transplantation may Prevent Development of Diabetes and Fatty Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)...  PAREXEL International Corporation (NASDAQ: PRXL ) ... Baird Healthcare Conference in New York.  Ingo Bank ... be making a presentation on PAREXEL and discussing business ... 2014. A live webcast of the discussion ... website at www.PAREXEL.com in the Upcoming Events ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2
... Switzerland, March 13 Arpida Ltd,(SWX: ARPN) announced today ... 2007 highlights, Major pipeline progress:, - ... cSSSI,achieves its pre-specified primary endpoint, as did the first, ... intravenous iclaprim in,cSSSI initiated, - First patients enrolled ...
... Innocoll, Inc., a,privately-held biopharmaceutical company, announced ... phase 2 clinical trials sponsored by its ... CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the management of ... SURGICAL IMPLANT is a biodegradable and fully,bioresorbable ...
... 13 Kansas has long,been known for its ... many have not realized, however, is that Kansas, ... far beyond the farm,-- namely, the scientific laboratory., ... and the,animal-health industry have positioned the state squarely ...
Cached Biology Technology:Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Op-Ed: The NBAF Would Build on Kansas' Existing Strengths in Bioscience 2
(Date:8/20/2014)... in this image of the Para and Mato Grosso ... likely intentionally set in order to deforest the land. ... of trees where the land is thereafter converted to ... forestland to farms, ranches, or urban use. The herringbone-patterned ... Amazon Rainforest in the middle of the image are ...
(Date:8/20/2014)... When are athletes who have suffered concussions ready to ... has found that high school athletes who head back ... experience a significant regression in their abilities to simultaneously ... as seen in changes in their balance and/or altered ... Ten of the 12 had returned to activity in ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... rainforests are often called the "lungs of the planet" because ... But the amount of carbon dioxide that rainforests absorb, or ... a paper published online this week (Feb 6 2013) by ... from the University of Exeter, the Met Office-Hadley Centre and ...
... A closer look at personalized or point-of-care healthcare ... in India organized and chaired by NJIT Distinguished ... Medicine and Biology Society (EMBS) International Special Topic ... the world, focused on topics ranging from 21st ...
... Virginia Commonwealth University Massey Cancer Center suggest that a ... potentially be an effective new therapy for several forms ... and mantle cell lymphoma (MCL). The study, ... showed that the experimental drug combination killed cancer cells ...
Cached Biology News:Lungs of the planet reveal their true sensitivity to global warming 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 3Experimental drug combination selectively destroys lymphoma cells 2
... sealed isolation chamber provides a safe, ... sterile pharmaceuticals, in accord with USP-797 ... 100 (ISO 5) cleanliness conditions in ... IV rod and tilt-up front panel ...
... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Selective media for Salmonella...
Biology Products: